Venetoclax overcomes resistance to all‐trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion

Abstract excerpt

Acute promyelocytic leukemia (APL) is generally driven by PML::RARA, but approximately 2% of variant APL patients do not contain this fusion gene and pose challenges in diagnosis and treatment. Here, we reported an aggressive APL patient with variant TNRC18::RARA fusion gene, who was resistant to standard differentiation induction therapy consisting of all-trans retinoic acid (ATRA) and arsenic trioxide but...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Protein Degradation and Inhibitors
• Share to Retinoids in leukemia and cellular processes